Home Tags Antibody-drug conjugate

Tag: antibody-drug conjugate

RemeGen’s RC88 Receives US FDA Fast Track Designation

The United States Food and Drug Administration has granted Fast Track Designation for China-based RemeGen's RC88, a mesothelin (MSLN)-targeting antibody-drug conjugate (ADC). The investigational drug is intended for the treatment of patients diagnosed with platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.

Validation of ADC Platform for Protein Concentration and the Drug-Antibody Ratio...

Antibody Drug Conjugates (ADCs) are biopharmaceutical drugs which are designed to treat cancer by targeting and killing the cancerous cells while leaving the healthy...

AJICAP Second-generation: Realizing Versatility and Robustness through Fc-Affinity Guided Chemical Conjugation...

Over the past decade, site-specific chemical conjugation has emerged as a promising strategy to produce antibody-drug conjugates (ADCs) in the field of oncology [1]. Daiichi-Sankyo's chemical conjugation method, which uses high drug-to-antibody ratio (DAR) technology, was approved by the U.S. Food and Drug Administration as the first site-specific ADC (fam-trastuzumab-deruxtecan-nxki; Enhertu® | Daiichi Sankyo and AstraZeneca).

Using AI in the Development of Novel ADCs: Lantern Pharma and...

Lantern Pharma has signed a research collaboration with Bielefeld University for the development of novel antibody-drug conjugates (ADCs) with high therapeutic and anti-tumor potential. The partners will be using Lantern's proprietary Response Algorithm for Drug Positioning and Rescue (RADR®) artificial intelligence (AI) and machine learning (ML) platform , to rapidly develop novel cryptophycin-antibody drug conjugates (ADCs), which represent an exciting class of potent and highly targeted drug candidates.

ATG-022, a Claudin 18.2 ADC, Receives Orphan Drug Designations for the...

Shanghai-based biopharmaceutical company Antengene, confirmed that ATG-022, a Claudin 18.2 (CLDN18.2) antibody drug conjugate (ADC) being developed by the company, has been granted two Orphan Drug Designations (ODD) consecutively by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and pancreatic cancer. 

Accelerating Biologics R&D with Unified Software and Data Flows

Biologics are changing the way we treat disease, affecting where companies invest, and, most importantly, impacting patients’ lives. Last year, nearly half of the 37 new drugs approved by the U.S. Center for Drug Evaluation and Research (CDER) were biologics, while its partner agency—the U.S. [1] Center for Biologics Evaluation and Research (CBER)—approved a dozen additional products. [2] These approvals span many modalities and cover a range of conditions, including many rare and hard-to-treat diseases.

LaNova Signs Exclusive License Agreement with AstraZeneca for Novel GPRC5D-Targeting ADC

LaNova Medicines and AstraZeneca have entered into an exclusive license agreement with  for LM-305, a pre-clinical stage antibody-drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D).

A Preclinical Profile of the Potential of BYON3521

A recent article, published in Molecular Cancer Therapeutics, an American Association for Cancer Research (AACR) journal, suggests that BYON3521, a next-generation antibody-drug conjugate being developed by clinical-stage Dutch...

Daiichi Sankyo and AstraZeneca Sign Collaboration with Lung Cancer Research Foundation;...

The Lung Cancer Research Foundation (LCRF), a leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve...

South Korean Chong Kun Dang Pharm Licenses Synaffix Platform Technology

South Korean's Chong Kun Dang Pharm (CKD) has entered a licensing agreement with Netherlands-based Synaffix for the development of novel antibody-drug conjugates (ADCs) with best-in-class therapeutic index.

X